需要订阅 JoVE 才能查看此. 登录或开始免费试用。
Method Article
我们提出了一个协议使用基质凝胶塞血管生成测定的变化来研究小鼠的人内皮周细胞的相互作用。
Angiogenesis is the process by which new blood vessels are formed from existing vessels. New vessel growth requires coordinated endothelial cell proliferation, migration, and alignment to form tubular structures followed by recruitment of pericytes to provide mural support and facilitate vessel maturation. Current in vitro cell culture approaches cannot fully reproduce the complex biological environment where endothelial cells and pericytes interact to produce functional vessels. We present a novel application of the in vivo matrix gel plug assay to study endothelial-pericyte interactions and formation of functional blood vessels using severe combined immune deficiency mutation (SCID) mice. Briefly, matrix gel is mixed with a solution containing endothelial cells with or without pericytes followed by injection into the back of anesthetized SCID mice. After 14 days, the matrix gel plugs are removed, fixed and sectioned for histological analysis. The length, number, size and extent of pericyte coverage of mature vessels (defined by the presence of red blood cells in the lumen) can be quantified and compared between experimental groups using commercial statistical platforms. Beyond its use as an angiogenesis assay, this matrix gel plug assay can be used to conduct genetic studies and as a platform for drug discovery. In conclusion, this protocol will allow researchers to complement available in vitro assays for the study of endothelial-pericyte interactions and their relevance to either systemic or pulmonary angiogenesis.
血管生成是由该新的血管从预先存在的血管网1在许多领域从正常发展到疾病形成和是正在进行的研究的焦点的过程。这种动态过程涉及的增殖和血管内皮细胞(ECS)和周构建血管管的朝向需要的氧气和营养输送2点定向招募的迁移。为了研究这个过程需要一个同样动态测定中,最重要的一个可以概括的管道形成三维性质。 体外 3D基质测定已经开发了满足这种需要,并已运作良好,使研究人员以限定在空间和时间上离散的步骤,其中的血管生成发生3,4,5,6。然而,这些体外 3D基质模型限于研究非灌注容器的ð因此缺乏相关的血管生成过程中的关键组件( 例如,循环增长和抑制因子,非自然的紧张/势力横跨血管床),并不能模拟存在于活组织的复杂环境。为了解决此限制,几个体内血管生成测定法已开发7,包括基质凝胶塞测定法,其将是我们的报告8,9的焦点。
基质胶栓法是一个行之有效的体内血管生成实验,呼吁研究人员,因为它提供了一个强大的平台,以测试在不同的血管细胞和物质的作用。基质凝胶是由在37℃下固化成凝胶样物质的Engelbreth-Holm的-群(EHS)小鼠肉瘤细胞系分泌的市售基底膜溶液。基质凝胶可与细胞和/或物质,如生长因子,和麟蹄混合皮下反恐执行局到鼠标。主机内皮细胞会侵入插头超过14天,形成血管网,并成为与宿主的血液灌注。迄今为止,基质凝胶塞测定已专注于内皮细胞行为的血管生成过程中的研究,但是,据我们所知的任何努力尚未作出判断该测定是否可用于共培养的内皮细胞和周细胞研究这两种细胞类型的血管生成过程中如何相互作用。具体地,理解的EC和周之间的关系是用于研究疾病,其中血管损失是病理性的,包括微血管缺血和周围血管疾病10,11,12有价值。
在这里,我们描述了引入了源于人的周细胞与人类内皮和成纤维细胞生长因子(bFGF)沿着矩阵凝胶混合物的协议。该混合物然后可以皮下注射我ñSCID小鼠的背部,使形成功能齐全,周细胞涂,混合型血管。我们的协议描述了如何制备含有人内皮有或没有人的周细胞,放置到SCID小鼠以及如何分析关键血管生成端点组织切片基质凝胶塞。
伦理学声明:涉及动物主题程序已在医学院斯坦福大学医学院被批准的机构动物护理和使用委员会。
注意:动物是在用3%的蒸发器异氟醚和O 2气体的3%的电源麻醉。眼睛上的药膏兽医使用可能有助于防止干燥时的麻醉下。
1.细胞的制备
2.基质凝胶制备
3.混合矩阵凝胶细胞
4.鼠标准备
5.矩阵注射凝胶
6.基质凝胶插件隔离:注射后14天
7.石蜡过程中的基质凝胶插件
8. HE染色(H&E)染色第13
9.染色其他幻灯片人类毛细血管和周
10.量化毛细血管密度和结构14
基质凝胶塞段的代表性H&E和免疫荧光染色, 如图2所示。节从EC仅插头显示一些血管被大多不与血液( 图2左上,黑色箭头),而含有插头灌注既内皮和周显示多个灌注血管直径较大和完整周细胞包裹,就证明了紧邻的CD31阳性内皮细胞阳性的SMA染色。这些结果表明,周细胞中的新生血管形成,而这动态过程可以概括并容易在体内
基质凝胶塞法已被证明是评估在血管发生, 在体内血管生成和抗血管生成的化合物基因调节,并以补充在体外试验方便和有效的方法。这里,我们详细描述人类血管生成的新颖基质凝胶塞测定该调查期间血管形成的内皮细胞和周细胞之间的相互作用。
还有在这个协议的几个新颖的关键步骤。在低通道(通道1 - 4)细胞是优选的,因为在14天的实验设置中年轻细?...
No competing financial interests enclosed.
Dr. K. Yuan was supported by an American Heart Association Scientist Development Grant (15SDG25710448) and the Pulmonary Hypertension Association Proof of Concept Award (SPO121940). Dr. V. de Jesus Perez was supported by a career development award from the Robert Wood Johnson Foundation, an NIH K08 HL105884-01 award, a Pulmonary Hypertension Association Award, a Biomedical Research Award from the American Lung Association and a Translational Research and Applied Medicine award from Stanford University.
Name | Company | Catalog Number | Comments |
PBS (Phosphate buffered saline) | Corning | 21-031-CV | |
0.25% Trypsin/0.53 mM EDTA | Corning | 25-053-CI | |
Endothelial Cell Media (ECM) kit | Sciencell | 1001 | includes media, EC growth supplement, and penicillin/streptomycin, each supplied at the appropriate volume for easy mixing |
Pericyte Media (PM) kit | Sciencell | 1201 | includes media, Pericyte growth supplement, and penicillin/streptomycin, each supplied at the appropriate volume for easy mixing |
primary human pulmonary microvascular endothelial cells | Pulmonary Hypertension Breakthrough Initiative | this cell type is also available commercially. Cells used at passage 1-4 | |
primary human pulmonary pericytes | Pulmonary Hypertension Breakthrough Initiative | this cell type is not available commercially, but brain paricytes are. Cells used at passage 1-4 | |
bFGF (basic Fibroblast Growth Factor) | Peprotech | 100-18B | stock solution is 50 μg/ml in 0.1% BSA in PBS, aliquots at 50 μl and stored at -20 degrees |
Matrigel Basement Membrane Matrix | BD | 356237 | |
28 G 1 cc Insluin Syringe | BD | 329410 | |
SCID (Severe Combined Immune Deficiency) mice | The Jackson Laboratory | 5557 | NOD.SCID IL2R gamma knockout strain is the best strain; 4-6 weeks of age |
1.5 ml microcentrifuge tubes, sterile | Thermo Fisher Scientific | 05-408-129 | |
15 ml screw top tubes, sterile | BD Biosciences | 352096 | |
PAP pen | Life Technologies | 8899 | |
hemocytometer | ThermoFisher Scientific | 02-671-6 | |
Nair hair removal cream | Walmart | ||
anti-human CD31 primary antibody | LifeSpan Biosciences | LS-B4737 | working solution is 1:50 |
anti-human Smooth Muscle actin CY3 primary fluorescent antibody | Sigma | C6198 | working solution is 1:300 |
goat anti-rabbit secondary antibody; 488/green | ThermoFisher Scientific | A-11008 | working solution is 1:250 |
Prolong Gold DAPI solution | Cell Signaling | 8961S | |
microscope slides | VWR | 48300-047 | |
no. 1.5 cover slips | Thermo Fisher Scientific | 12-544-D | |
citrate buffer 10x | Millipore | 21545 | |
extra fine surgical scissors | Fine Science Tools | 14084-08 | |
Formalin (paraformaldehyde) | Thermo Fisher Scientific | 245-685 | |
Tissue cassettes | Simport | M492-12 | |
goat serum | Dako | X0907 |
请求许可使用此 JoVE 文章的文本或图形
请求许可This article has been published
Video Coming Soon
版权所属 © 2025 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。